Lisinopril
- Generic Name
- Lisinopril
- Brand Names
- Prinivil, Qbrelis, Zestoretic, Zestril
- Drug Type
- Small Molecule
- Chemical Formula
- C21H31N3O5
- CAS Number
- 76547-98-3
- Unique Ingredient Identifier
- 7Q3P4BS2FD
- Background
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.
Lisinopril was granted FDA approval on 29 December 1987.
- Indication
Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.
- Associated Conditions
- Acute Myocardial Infarction (AMI), Cardiovascular Events, Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Migraine
A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06772779
- Locations
- 🇺🇸
Celerion (Site 0001), Tempe, Arizona, United States
OptiZ: Real World Evidence Study
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Closed Loop Medicine
- Target Recruit Count
- 113
- Registration Number
- NCT06745726
- Locations
- 🇬🇧
Oak Street Medical Practice, Norwich, United Kingdom
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
- Conditions
- Prostate CancerRadiation ToxicityUrinary Complication
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 30
- Registration Number
- NCT05530655
- Locations
- 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States
Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 38
- Registration Number
- NCT05061901
- Locations
- 🇷🇺
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl", Yaroslavl, Yaroslavl Region, Russian Federation
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Conditions
- Renal Insufficiency, ChronicHyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (SZC)Drug: Placebo
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 716
- Registration Number
- NCT05056727
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Eastern Virginia Medical School
- Registration Number
- NCT05016440
- Locations
- 🇺🇸
Eastern Virginia Medical School, Norfolk, Virginia, United States
Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects
- Conditions
- Therapeutic Equivalency
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 92
- Registration Number
- NCT04885660
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
- Conditions
- Hepatocellular CarcinomaNonalcoholic Steatohepatitis
- Interventions
- Procedure: Biospecimen CollectionProcedure: Liver Ultrasonographic ElastographyProcedure: Magnetic Resonance ElastographyProcedure: Magnetic Resonance ImagingProcedure: Proton Density Fat FractionOther: Questionnaire Administration
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 45
- Registration Number
- NCT04550481
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
Centrally Acting ACE Inhibition in SLE
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 36
- Registration Number
- NCT04486118
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Northwell Rheumatology, Great Neck, New York, United States
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
- Conditions
- LymphomaHematopoietic and Lymphoid Cell NeoplasmBreast CarcinomaSarcoma
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04190433
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.